Skip to content
Search

Latest Stories

PDA urges pharmacy schools to communicate process of in-person exams in advance

The Pharmacists' Defence Association (PDA) has raised the issue faced by the pharmacy students on returning to in-person assessments while urging the universities to take an empathetic approach in transition of online to in-person exams.

It was highlighted by the association that many student members were apprehensive about the return to in-person assessments. This is due to their continuing worry of Covid-19 transmissions and anxiety caused by changing exam formats and procedures.


However, with the ease of Covid restrictions, now pharmacy schools are able to decide how exams are conducted but the PDA believes that they should communicate the process to students in advance.

“A return to normal university life is considered to be beneficial to student health and well-being. In-person exams are an important part of preparing for students’ future trainee assessment examinations, GPhC accreditation for pharmacy schools, and ensuring the integrity of exam results. As future healthcare professionals, face-to-face interaction is also an integral part of the role,” said the PDA.

“Communication with students is crucial. For some students, this will be their first time taking in-person examinations, and all will need to adjust to these changes and prepare accordingly. The PDA asks that universities provide students with any additional support needed.”

The association suggested: “Where possible, universities should communicate to students any considerations they are taking to mitigate the potential effects the change to in-person exams may have on students’ grades.”

Universities have a duty of care for the health, safety, and well-being of students and staff including during the assessment period, it said, adding that risk assessments and considering safe practices such as social distancing and ventilation are important to ensuring that students feel safe to sit their exams.

The PDA also encouraged students who have a disability and may be eligible for a reasonable adjustment to apply for one. It said: “Please remember that adjustments may be for mental health as well as physical health and that medical evidence is required. Students should refer to their universities’ reasonable adjustment policy.”

The PDA’s advice is that members should ask for a reasonable adjustment if they feel it would be beneficial to making their examination experience equal to those who do not need an adjustment.

The PDA is advising students who are in high-risk groups or live with someone who is at high-risk in relation to Covid-19 infection to speak to their personal tutor about their individual circumstances and additional support they may require. Pharmacy students can contact their PDA student reps if they have any further issues or contact the PDA service centre.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less